Rare Cancer Diagnosis, Tour de France Dream

A man told he has an incurable blood cancer decided to chase the Tour de France instead of a recliner.

Story Snapshot

A rare lymphoma diagnosis pushed Christopher Edgerton toward bigger cycling goals, not the couch.
Doctors warned of thickened blood, strokes, and heart attacks, yet he trained for brutal endurance rides.
His cross-country ride and later Tour de France mission aimed to turn fear into research money and awareness.
The story sits at the crossroads of real illness, personal grit, and big-institution storytelling.

A rare cancer that should have slowed him down

Christopher Edgerton was a working, active adult when a simple problem showed up: he felt worn out all the time. At his annual physical, routine blood work came back off, and his doctor sent him to Mayo Clinic for more tests.^[4] There, a hematologist told him he had Waldenström’s macroglobulinemia, a rare and incurable type of lymphoma that thickens the blood and can trigger clots, strokes, or heart attacks.^[2]^[1] Most people would hear that and think “slow down or else.”

The Mayo oncologist, Dr. Sikander Ailawadhi, did not sugarcoat it. He explained that this cancer can show up as numb hands and feet, large tumor-like growths, and blood so thick it strains the heart.^[2] Standard care often starts with “watch and wait,” then moves to drug combinations when symptoms rise.^[1] For Christopher, the team built a limited-time treatment plan with one clear goal: ease symptoms while keeping his independence and daily life intact.^[2] That goal mattered more than any lab number.

From diagnosis to a cross-country ride

Many patients respond to a rare cancer diagnosis by shrinking their world. Christopher made his bigger. After hearing his disease was treatable but not curable, he says he became keenly aware of time and wanted to get as much out of it as possible.^[2] Instead of giving up his bike, he set a huge target: ride from Los Angeles to Boston, coast to coast, and raise money for blood cancer research along the way.^[4]

Mayo Clinic later reported that he completed that ride, reaching the Atlantic 48 days after leaving Los Angeles and covering about 3,424 miles.^[4]^[7] A guest post by his wife describes the grind of that trip, the small-town stops, and the quiet army of friends, donors, and strangers who helped.^[7] That campaign brought in more than forty thousand dollars for research, with one tally citing over forty-seven thousand dollars donated.^[7] The exact audited figure may vary, but the ballpark impact is hard to dismiss.

Cycling as coping, mission, and message

On his own site, Christopher writes that his 2017 diagnosis turned cycling into more than a hobby; it became a way to live with lymphoma and stay connected to his health.^[3]^[5] He committed to a larger fundraising goal of one hundred thousand dollars because, as he puts it, research matters.^[3] His social media echoes that theme, tying long rides to blood cancer awareness days and to gratitude for modern treatments that let him pedal at all.^[5]^[9]

There is no formal psychological test in the public record proving that cycling “works” as therapy for him. What we have instead are his words and his actions over years. Across that span, the pattern is steady: rising mileage, bigger events, and fundraising tied to his diagnosis.^[2]^[3]^[4]^[6] For many conservative readers, that combination of personal responsibility, hard work, and voluntary charity carries more weight than another survey score would.

Chasing the Tour de France with cancer under control

Once his disease came under good control, Christopher and his care team agreed he could travel and “do what he wants to do,” with the clear understanding that future treatment may be needed again.^[2] That window of relative stability set up his next audacious idea: ride the entire route of the 2026 Tour de France one week ahead of the professionals, as part of an event to raise awareness for blood cancers.^[2]^[3]^[6]

That pre-Tour effort, by design, is as much a megaphone as it is a bike ride. It fits a broader pattern in rare disease advocacy, where personal stories move people to learn, give, and sometimes support policy change.^[11]^[14]^[17] The upside is obvious: more eyes on a rare cancer that needs research dollars. The risk, for skeptics, is that Mayo Clinic’s polished storytelling and the emotional pull of one man’s grit can overshadow harder questions about evidence, money flows, and how typical his story really is.